The primary objectives were to compare the incidences of severe thrombocytopenia, critical thrombocytopenia and a relative decline in platelets from baseline (≥50% decline) between patients receiving linezolid and those receiving vancomycin. The secondary objective was to assess the relationship between vancomycin trough concentration and adverse platelet outcomes. Results: The study included 502 patients (251 matched pairs). The occurrences of platelet counts ≤50 000 cells/mm 3 and ≤20 000 cells/mm 3 did not differ significantly between linezolid and vancomycin patients. A ≥50% decline in platelets from baseline was observed in 78 (31.1%) patients receiving vancomycin and 43 (17.1%) patients receiving linezolid (risk ratio 0.55; 95% CI 0.40 -0.77). A clear exposure-response relationship was observed between vancomycin trough concentration and ≥50% decline in platelets from baseline.
Introduction
Linezolid is generally well tolerated, but its use in the clinical setting is often limited by the potential for toxicity, mainly thrombocytopenia. 1 While this is a recognized toxicity of linezolid, surprisingly there have been only a limited number of welldesigned comparative cohort studies comparing the incidence of thrombocytopenia between patients receiving linezolid and other anti-Gram-positive agents. 2 To date, most comparisons have been limited to data from clinical trials. 3 -7 While clinical trials provide valuable information on efficacy, the adverse effect profiles of patients enrolled in clinical trials may not be fully reflective of the diverse patient populations that use the drugs in practice. Furthermore, previous evaluations primarily examined average risk during therapy and did not include time to event analyses with censoring. 2 -7 Since the risk of thrombocytopenia increases over time, it is critical to examine how risk changes as a function of therapy duration in order to place results in proper perspective. 8 The intent of this study was to determine whether linezolid causes significant thrombocytopenia that might endanger patients more often than vancomycin. To assess this, the primary objectives of the study were to compare the incidences of platelet counts ≤50000 cells/mm 3 , platelet counts ≤20 000 cells/mm 3 and ≥50% decline in platelets from baseline between patients receiving linezolid and those receiving vancomycin therapy in the Upstate New York Veterans' Affairs (VA) Health Care Network or Veterans' Integrated Service Network 2 (VISN 2). These two low platelet count threshold endpoints (≤50 000 cells/mm 3 and ≤20 000 cells/mm because they have been identified in the literature as significantly low platelet levels that might endanger patients. 9 -13 A platelet count ≤50000 cells/mm 3 is considered severe thrombocytopenia due to the potential for spontaneous bleeding in certain high-risk patient populations. A platelet count ≤20000 cells/ mm 3 is the critically low platelet count at which patients should be considered for platelet transfusion. 9, 10, 12, 13 For drug-induced thrombocytopenia, another important consideration is the relative change from baseline; many experts consider the relative change from baseline to be of greater importance than the absolute platelet count. 14 -18 For this, we examined a ≥50% change in platelets from baseline since this change has been identified as the threshold for diagnosis of a drug-induced thrombocytopenia. 14, 15 A secondary objective of this study was to assess the relationship between vancomycin trough concentration and adverse platelet outcome. Earlier studies suggested that high-intensity and prolonged exposure to vancomycin may lead to reduction in platelet counts. 19 However, the relationship between vancomycin exposure and thrombocytopenia has not been quantified in the '15 -20 mg/L' vancomycin trough era. 20 
Methods

Study design and population
A matched cohort study was performed among patients in the Upstate New York VA Healthcare Network from January 2005 until February 2008. Eligibility criteria were: (i) receipt of linezolid or vancomycin therapy for ≥48 h; (ii) initiation of linezolid or vancomycin therapy as an inpatient; and (iii) baseline platelets available for evaluation. Patients on linezolid for ≥48 h were matched 1 :1 to those on vancomycin. Matching criteria were (i) location at the start of therapy [intensive care unit (ICU) or non-ICU], (ii) admission hospital within VISN 2, (iii) length of stay (LOS) prior to initiation of therapy +7 days, (iv) age (,50, 50-70 or .70 years) and (v) baseline platelets (≤100000 or .100000 cells/ mm 3 ). If multiple patients receiving vancomycin satisfied these criteria, a random number generator was used to select a patient for the study.
The research was conducted in accordance with the Declaration of Helsinki and national and institutional standards. The study was approved by institutional review boards at both the Samuel S. Stratton VA Medical Center and Albany College of Pharmacy and Health Sciences (expedited approvals). Due to the retrospective nature of the study, a waiver of consent was obtained.
Data collection
Data were extracted by trained reviewers and included demographics, comorbidities, hospitalization history, antibiotic therapy, disease severity, concomitant medications, microbiological data, source of infection and laboratory data.
Demographic characteristics included age, sex, height and weight. Comorbidities included diabetes mellitus, heart failure, chronic obstructive pulmonary disease, hypertension, hepatic dysfunction, renal dysfunction (defined by need for renal replacement therapy), transplanted organ, active malignancy or cancer, immunosuppressive drugs (prednisone .20 mg/day or equivalent corticosteroid ≥14 days prior to culture, or the receipt of any antineoplastic chemotherapy in the 3 months prior to culture), decubitus ulcers, HIV infection, history of cerebrovascular accident, alcoholism and surgery requiring .48 h of hospitalization in the 30 days preceding the initiation of antibiotic therapy. All hospitalizations for .72 h in the 180 days preceding the current hospitalization were documented.
Medication usage was captured for each patient from 35 days prior to the start of linezolid or vancomycin therapy and ending 14 days after discontinuation of treatment. Because of the high usage of medications known to cause thrombocytopenia, the definition of concomitant cytotoxic medication was restricted to those with a .1% incidence of thrombocytopenia. These medications were abciximab, diclofenac, eptifibatide, sirolimus, tamoxifen, valproic acid and chemotherapeutic agents with an incidence of thrombocytopenia .1% as documented within the medical literature. 21 Use of heparin and low molecular weight heparins was also captured. Concomitant antibiotic use for ≥48 h was collected. Use of non-steroidal anti-inflammatory agents was recorded. 22 Severity of illness at the initiation of therapy was captured using the Acute Physiological and Chronic Health Evaluation (APACHE-II) based on the patient's worst physiological score within the 24 h prior to the initiation of linezolid or vancomycin therapy. 23 Recording of complete blood count data was started 5 days prior to the initiation of linezolid or vancomycin therapy and ended 3 days after the discontinuation of therapy. All vancomycin trough concentrations obtained during the hospitalization were documented. For these analyses, we focused on the highest trough concentration within the first 7 days of therapy, categorized as 0 -10, 10.1 -20 and ≥20.1 mg/L. Microbiological culture and susceptibility data were collected 5 days prior to the start of linezolid or vancomycin therapy, ending 2 days after the initiation of therapy. The indication for treatment was categorized as bloodstream, urinary tract, skin and skin structure/osteoarticular, intra-abdominal, respiratory or other/unknown. If a patient had multiple indications for therapy, the indication with the highest risk of mortality was used to classify the source of infection.
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Outcomes
The primary outcomes examined were (i) severe thrombocytopenia (platelet count ≤50000 cells/mm 3 ), (ii) critical thrombocytopenia (platelet count ≤20 000 cells/mm 3 and (iii) ≥50% decline in platelets while on therapy relative to baseline platelet count. 9 -13 The occurrence of these three adverse platelet outcomes was assessed at any point during treatment and days 7, 14, 21 and 28 post-initiation of therapy. As in other studies, only one 'on-treatment' platelet value was necessary to meet one of the definitions of thrombocytopenia. Determination of outcome status was not restricted to patients with only one post-treatment outcome reading. 2, 3 Patients with baseline platelets ≤50000 cells/mm 3 or ≤20 000 cells/mm 3 were not included in analyses for severe thrombocytopenia or critical thrombocytopenia, respectively. All patients were eligible for the analysis of ≥50% decline in platelets from baseline. Percentage change in platelets from baseline was calculated as follows: (platelets baseline 2platelets lowest-value-on-therapy )/platelets baseline .
Statistical analyses
For the bivariate analyses comparing linezolid and vancomycin, categorical variables were compared using McNemar's test or the Wilcoxon matched pairs test. Continuous variables were compared using the paired t-test or the Wilcoxon signed rank test. When the expected cell frequency was low for categorical variables, the exact probabilities from a binomial distribution were utilized to compare treatment groups. Clinical and demographic characteristics associated with each adverse platelet outcome were compared using the x 2 test for categorical variables. Continuous variables were assessed using Student's t-test and the Mann-Whitney U-test. For analyses where the expected cell frequency was low, Fisher's exact test was utilized.
Time-to-event analyses were performed by computing Kaplan-Meier estimators (product-limit method) for each of the adverse platelet outcomes under study (platelets ≤50000 cells/mm 3 , platelets ≤20 000 cells/mm 3 and platelet decline ≥50% from baseline). Survival distributions were compared using the log-rank test. A series of stratified Patel et al.
analyses were performed to assess effect measure modification. Poisson regression and multivariate Cox proportional hazards regression analyses were performed to determine whether treatment was independently associated with each adverse platelet outcome. 26, 27 All baseline covariates associated (P,0.2) with the outcome of interest and present in ≥5% of the study population were considered as potential confounders. If the resulting risk ratio or hazard ratio for the treatment group changed by .10%, the variable was retained in the model as a confounder. The process was repeated until all potential confounders were assessed. Multiplicative effect measure modification was also assessed through the use of interaction terms in the multivariate models. All calculations were computed using SAS version 9.1 (SAS, Cary, NC, USA) or SPSS version 11.5 (SPSS, Chicago, IL, USA).
Results
During the study period, 298 inpatients were initiated on linezolid therapy for ≥48 h; among these, 271 patients had baseline platelet data. Of the 271 linezolid patients, 251 were successfully matched to 251 patients on vancomycin therapy from a pool of 2408 patients on vancomycin therapy for ≥48 h during the study period. All 251 matched pairs were eligible for the platelets ≤20 000 cells/mm 3 and platelet decline ≥50% from baseline outcome analyses. Of the 251 matched pairs, only 248 matched pairs were eligible for the platelet count ≤50000 cells/mm 3 analyses; 3 linezolid patients had a baseline platelet count ≤50 000 cells/mm 3 . There were no cases of adverse platelet outcomes among the 20 linezolid recipients that could not be successfully matched.
The matching criteria, demographics and clinical characteristics of the study population are displayed in Table 1 . Overall, the matching algorithm was successful and the frequencies of each of the categorical matching criteria were identical. The only matching variable to differ significantly was the continuous calliper-matched variable, LOS prior to initiation of therapy. Median [interquartile range (IQR)] LOS prior to initiation of therapy was higher for linezolid than for vancomycin recipients [7 (3 -16 ) versus 3 (1 -12) days, respectively]. Despite tight matching, several baseline covariates differed between groups. Hospitalization in the preceding 6 months for .72 h was more frequent among the linezolid group. The use of chemotherapeutic medications associated with a .1% incidence of thrombocytopenia was more frequent among the linezolid group relative to the vancomycin group (6% versus 1.2%, respectively, P ¼ 0008). Baseline platelet counts were also higher among linezolid patients relative to vancomycin patients. Additionally, there were several significant differences in distributions of comorbidities, pathogens and indications for therapy between groups. Beyond baseline characteristics, a longer median (IQR) duration of antibiotic therapy was observed for the linezolid group relative to the vancomycin group [10 (6 -15) versus 7 (4 -12) days, respectively]. Despite differences in median duration of therapy, the median (IQR) number of platelet readings did not significantly differ between linezolid and vancomycin recipients [5 (2 -9) and 5 (3 -9) readings, respectively].
Results of the bivariate comparisons between adverse platelet outcomes and treatment groups are displayed in Table 2 . The cumulative incidences of severe thrombocytopenia (platelets ≤50 000 cells/mm 3 ) and critical thrombocytopenia (platelets ≤20 000 cells/mm 3 ) at any point in therapy did not differ statistically between treatment groups. Of note, the cumulative incidence of severe thrombocytopenia at any point during therapy was higher among linezolid patients relative to vancomycin recipients [3.6% versus 1.2%, respectively, risk ratio (RR) 3.00], but the 95% CI (0.82-10.99) spanned 1. In contrast, the cumulative incidence of critical thrombocytopenia at any point during therapy was lower among linezolid patients relative to vancomycin recipients (0.8% versus 1.2%, respectively; RR 0.67), but the 95% CI (0.11 -3.95) again included 1. A statistically significant difference in the cumulative incidence of platelet decline ≥50% at any point in therapy was detected between groups: 17.1% among linezolid recipients and 31.1% among vancomycin recipients (RR 0.55; 95% CI 0.40-0.77).
The risks of adverse platelet outcomes at the defined time thresholds (days 7, 14, 21 and 28 post-initiation of therapy) are also displayed in Table 2 . The cumulative incidences of severe thrombocytopenia and critical thrombocytopenia did not differ widely over time between linezolid and vancomycin recipients. The frequency of a ≥50% decline in platelets from baseline increased monotonically over time among both linezolid and vancomycin recipients. Consistent with the overall analysis, the risk of ≥50% decline in platelets from baseline was less pronounced in the linezolid group relative to the vancomycin group across all time strata.
Clinical and demographic characteristics associated with the three adverse platelet outcomes are displayed in Table S1 (available as Supplementary data at JAC Online). All variables associated with adverse platelet outcome in the bivariate analysis (P,0.2) and present in ≥5% of the study population were assessed as potential confounders in each Poisson regression analysis at model entry. Results of the Poisson regression analyses that adjusted for potential confounding variables are displayed in Table 2 . Overall, the adjusted RRs (95% CI) for the severe thrombocytopenia analyses were largely consistent with unadjusted measures of association. For critical thrombocytopenia, the Poisson regression algorithm did not converge due to the small number of events and the adjusted measures of association could not be computed.
Kaplan -Meier plots of each of the adverse platelet outcomes are displayed in Figure 1(a-c) . Overall, the median (IQR) change in platelets from baseline to the most extreme value on therapy was 241 (2109, +8) among linezolid recipients and 29 (262, +106)×10 3 cells/mm 3 among vancomycin recipients (P,0.001). For severe thrombocytopenia (Figure 1a ) and critical thrombocytopenia (Figure 1b) , there were no significant differences in survival distributions. However, a significant difference in the survival distributions was noted between treatment groups for ≥50% decline in platelets (Figure 1c) . While survival curves appeared to be similar during the first 5 days of therapy, a more dramatic drop in the survival probability was observed for those on vancomycin relative to linezolid beyond day 5. For each of the analyses, no substantive departures from homogeneity were observed when the data were stratified on baseline platelet category, creatinine clearance ≤50 mL/min, the presence of three or more comorbid conditions and hospitalization in the preceding 180 days. No statistically significant association between linezolid and severe thrombocytopenia was observed in the Cox regression analysis that controlled for all variables associated with severe thrombocytopenia in the bivariate analysis (P,0.2) and present in ≥5% of the study population (hazard ratio 2.87; 95% CI 0.76 -10.85). For the critical thrombocytopenia model, there was no statistically significant association between linezolid and platelets ≤20000 cells/mm 3 after adjustment for potential confounding variables (hazard ratio 0.97; 95% CI 0.15 -6.33). The multivariate Cox regression model examining ≥50% decline in platelets demonstrated a significant association between linezolid and ≥50% decline in platelets from baseline (hazard ratio 0.40; 95% CI 0.27 -0.58) after adjustment for potentially confounding baseline characteristics.
If one were to make linezolid the referent, the hazard ratio for vancomycin was 2.53 (95% CI 1.73-3.69).
Among patients receiving vancomycin therapy, there were 170 (67.7%) with a vancomycin trough concentration drawn during the first 7 days of therapy. The relationship between categorized vancomycin trough concentration and the risk of ≥50% decline in platelets from baseline is displayed in Figure 2 . There was a significant vancomycin exposure-response relationship between the highest vancomycin trough concentration in the 
Discussion
In a population that is particularly vulnerable to medicationrelated adverse events, we observed a low frequency of either severe or critical thrombocytopenia in patients receiving linezolid or vancomycin therapy. These two low platelet count threshold endpoints (≤50000 and ≤20000 cells/mm 3 ) were selected because they have been identified in the literature as significantly low platelet levels that might endanger patients. 9 -13 The cumulative incidences of platelets ≤50000 and ≤20000 cells/mm 3 at any point in therapy were low (,4%) in both treatment groups and clinically comparable. We also evaluated the cumulative Adjusted for chronic obstructive pulmonary disease, decubitus ulcers, transplant, use of immunosuppressive agents, surgery requiring .48 h of hospitalization in preceding 30 days, number of comorbidities, hospital ward at initiation of therapy, duration of therapy, APACHE-II score, baseline platelet category, methicillin-resistant Staphylococcus aureus infection, source of infection, use of nephrotoxic agents, heparin use, cancer drugs associated with thrombocytopenia, b-lactams, penicillins, fourth-generation cephalosporins, and aztreonam and macrolides.
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incidence of these adverse platelet outcomes at 7 day posttreatment intervals, and the measures of association were largely consistent with the overall adverse platelet outcomes analyses. Additionally, we compared the time to each of these outcomes; survival distributions were similar between treatment groups, and appeared to be nearly identical when displayed graphically. Finally, treatment was not associated with either of these outcomes after adjustment for the presence of potentially confounding baseline characteristics in .5% of the study population in the multivariate analyses. Collectively, these data indicate that the frequency of severe thrombocytopenia and critical thrombocytopenia does not appear to differ significantly among patients receiving linezolid or vancomycin.
These findings are consistent with previous evaluations. 2, 3 In an evaluation of thrombocytopenia risk (defined as ≤150000 platelets/mm 3 ) among 686 patients with nosocomial pneumonia enrolled in two randomized trials, the incidence of thrombocytopenia was 6.4% among linezolid recipients and 7.7% among vancomycin recipients. 3 Similarly, a study of 65 orthopaedic patients reported similarly low risks of haematological effects among patients receiving long-term therapy with either vancomycin or linezolid. 2 The incidence of thrombocytopenia (,150×10 9 platelets/L) was 5.1% and 3.3% among vancomycin and linezolid recipients, respectively. 2 For more severe thrombocytopenia (,100×10 9 platelets/L), the incidence was 0.9% and 1.4% among vancomycin and linezolid recipients, respectively. 2 A recent meta-analysis of nine randomized trials examining linezolid versus glycopeptides for the treatment of nosocomial pneumonia demonstrated an elevated risk of thrombocytopenia among patients receiving linezolid. 28 However, the interpretation of these results is unclear since the definitions of thrombocytopenia were not consistent across the studies. 28 A noteworthy, yet unanticipated, finding in this study was the nearly 2-fold increase in the proportion of patients with a ≥50% decline in platelets from baseline in the vancomycin group. Additionally, we observed a linear exposure-response relationship between the highest vancomycin trough concentration in the first 7 days of therapy and a ≥50% decline in platelets from baseline. Among patients with vancomycin trough concentrations between 0 and 10 mg/L, the probability of this outcome was comparable to that of patients receiving linezolid therapy. However, when trough concentrations were between 10.1 and 20 mg/L, the risk of a ≥50% decline in platelets nearly doubled. This is alarming because vancomycin consensus guidelines advocate maintaining higher trough concentrations between 15 and 20 mg/L for serious infection types. 20 While vancomycin-induced immune thrombocytopenia has been described in the literature, it has generally been considered to be a rare but potentially life-threatening event. 19,29 -33 The relatively high frequency of a ≥50% decline in platelets observed in our study among vancomycin recipients is suggestive of an alternative mechanism that should be explored in future studies. It will also be important to delineate which pharmacokinetic exposure best predicts a ≥50% decline in platelets so that an appropriate exposure target associated with this outcome can be identified. Additionally, these studies should attempt to determine which patients with 'therapeutic' 20 vancomycin trough concentrations are at greatest risk of a ≥50% decline in platelets, as well as which concurrent conditions augment the risk of vancomycin-induced thrombocytopenia.
Several considerations should be noted when interpreting these data. First, the duration of treatment for most patients was ,21 days; sparse data make estimates of thrombocytopenia unstable and imprecise beyond 21 days. This is an important limitation to note because this threshold is the critical point at which the risk of thrombocytopenia increases. 8 Second, this study focused on patients receiving care at VA medical centres. The choice of study population may limit the ability to generalize these results to other populations. However, this is an ideal study population for the research question because the relatively homogeneous patient population maximizes internal validity. While a more mixed population might improve generalizability, it compromises the internal validity by yielding too few patients across important confounders, ultimately resulting in unstable and biased measures of association. An additional advantage of the VA population is the closed healthcare system, which improves follow-up data collection; the VA database integrates inpatient and outpatient records throughout the VISN 2 network. Such extensive data capture lessens the potential for outcome misclassification.
Third, we did not collect any data on bleeding complications. The sensitivity and specificity of bleeding complications within medical records is imperfect. It is uncertain whether the imperfection in sensitivity/specificity is distributed in an independent and non-differential fashion across treatment groups. To offset this variability, we restricted our analyses to outcomes that could be objectively quantified and were not subject to detection bias or charting practices. Fourth, we recognize that concerns associated with myelosuppression are not limited solely to platelets. Other cell lines may be involved. In a post hoc analysis, we attempted to compare the proportion of patients with neutropenia during antibiotic therapy and found the frequency to be extremely low. Of the eight patients who had neutropenia while receiving antibiotic therapy, three were neutropenic prior to therapy and the remaining five were split between vancomycin (n¼ 3) and linezolid (n¼ 2) recipients. Fifth, there are a number Adverse platelet outcomes among linezolid and vancomycin recipients of complementary patient factors that may enhance the risk of adverse platelet outcomes. We collected data on medications known to cause thrombocytopenia. However, we did not comprehensively collect data on all factors associated with thrombocytosis. These factors include epinephrine, intravenous immunoglobulin, corticosteroids, tretinoin, vincristine, malignancy and splenectomy. In our study population, we did collect information on malignancy and vincristine use. The frequency of malignancy did not differ significantly between vancomycin and linezolid recipients (Table 1) . Additionally, there were only two patients in the entire study population that used vincristine. While thrombocytosis may potentially be a modifying variable, it is unclear how many patients would have factors associated with thrombocytosis and whether the overall results of our study would have changed after controlling for this variable. Furthermore, we did not collect data on disseminated intravascular coagulation, septic shock and other measures of sepsis severity. Among the patients in this study, the average APACHE-II score was 12, which is typically only associated with a ,15% predicted risk of hospital death. Thus, it is undetermined whether control for these sepsis-related variables would have affected our measures of association. Future studies should consider collection of these potentially modifying variables. It should be noted that if a patient was to experience an adverse platelet outcome secondary to sepsis or septic shock, it would most likely have occurred early during the course of therapy. 34 The KaplanMeier curves and day 7 comparisons suggest that sepsis-related cases of thrombocytopenia were likely uncommon since most cases of thrombocytopenia occurred after 5 days of therapy. The pattern of adverse platelet events observed in this study was most consistent with drug-induced thrombocytopenia due to marrow suppression (delayed occurrence). 13 Sixth, our sample size was limited and not powered to distinguish subtle differences in the small effect sizes observed for the frequencies of severe thrombocytopenia and critical thrombocytopenia between vancomycin and linezolid recipients. For severe thrombocytopenia, .1200 patients would have been required to detect an effect size of 2.4%. For critical thrombocytopenia, .20 400 patients would have been necessary to observe an effect size of 0.4%. Within VISN 2, this was not feasible since we were limited by the number of linezolid recipients within the study period. Finally, one of our matching variables, median length of stay prior to initiation of therapy, was higher for linezolid recipients than for vancomycin recipients. Adjustment for this difference did not change our measures of association. The mismatch most likely occurred as a result of the size of our calliper (+7 days). Future studies that match for this variable should consider using a tighter calliper, such as +3 days or an exact match.
Overall, this study found similarly low frequencies of severe thrombocytopenia and critical thrombocytopenia among veterans receiving linezolid or vancomycin. The risk of a ≥50% decline in platelets from baseline was significantly higher among patients receiving vancomycin therapy compared with patients receiving linezolid. While very few patients achieved critically low platelet counts, a decline in platelets ≥50% is not trivial and merits further aetiological assessment. Furthermore, a dose-response relationship was observed between a ≥50% decline in platelets and vancomycin trough concentration. Based on these data, vigilance for platelet monitoring should also be advocated for patients receiving either drug, particularly those achieving the higher trough concentrations recommended by the vancomycin consensus guidelines. 20 
